Introduction {#sec1-1}
============

HER2-positive Breast Cancer (BC) is the most aggressive subtype of BC, where the patient has a decreased overall survival and differential responses to chemotherapeutic and hormonal agents (Berry et al., 2000). HER2-positive cancers are characterized by overexpression and/or amplification of ERBB2 gene (HER2) (Slamon et al., 1987; Slamon et al., 1989). Human epidermal growth factor receptor 2 (Her2) is a tyrosine kinase receptor. In invasive breast carcinomas, it is overexpressed or amplified in 20 to 25% of patients (Slamon et al., 1987). Her2 overexpression may lead to increased receptor homo/heterodimerization which induces phosphorylation of the intracellular domain and leading to activation of many downstream signaling molecules, including class A phosphoinositide 3-kinases (PI3K)/AKT. Activated PI3K catalyzes the phosphorylation of inositol lipids to produce phosphatidylinositol-3,4,5-trisphosphate (PIP3), which is dephosphorylated to PIP2 by phosphatase and tensin homolog (PTEN). PTEN is a lipid phosphatase which is acting directly as an inhibitory of PI3K pathway. In sporadic breast cancer, it is infrequently mutated (5%). Approximately 25% of breast cancer cases have decreased expression of PTEN (Saal et al., 2005; Saal et al., 2008). In the downstream signaling, PIP3 activates the serine/threonine kinase AKT which in turn regulates the mammalian target of rapamycin (mTOR) (Barbareschi et al., 2012).

Activating mutations in *PIK3CA* have been found in several cancers, including breast cancer (Slamon et al., 1987; Berry et al., 2000; Zhao and Vogt, 2008). 80% of *PIK3CA* mutations occurs in exons 9 (helical domain) and 20 (kinase domain) which lead to changing in the amino acids sequence and increasing the protein activity (Engelman et al., 2006; Zhao and Vogt, 2008). Mutant *PIK3CA* encodes the p110α catalytic subunit of PI3K enzyme leads to activation of PI3K/AKT signaling pathway which is frequently involved in several cellular processes required for breast cancer development (Isakoff et al., 2005; Engelman et al., 2006). Of note, a previous study found that patients with *PIK3CA* mutation and amplified HER2 are less responsive to HER2 inhibitors, reflecting prognostic and therapeutics importance of mutation testing (Berns et al., 2007; Cizkova et al., 2012; Goel and Krop, 2015).

In Egypt, so far, there is no data available about *PIK3CA* mutations frequency in HER2-positive breast cancer patients. Since the *PIK3CA* mutation status could be useful potential prognostic and chemotherapy detection marker, we analyzed *PIK3CA* mutations in a series of 51 patients with Her2-positive BC to investigating the mutations frequencies and their correlation to clinical and pathological parameters.

Materials and methods {#sec1-2}
=====================

Patients and samples {#sec2-1}
--------------------

Formalin fixed paraffin embedded (FFPE) sections were collected from 51 female Egyptian patients, who were diagnosed with HER2 positive breast cancer between 2007 and 2013. Clinical and pathological information, including age, tumor type, tumor grade, marital and menopausal status, lymph nodes, HER2 score and ER and PR status, were collected.

The samples were recruited from the National Cancer Institute in cooperation with the Early Cancer Detection Unit of Ain Shams University Maternity Hospital. The study was approved by the ethics committee of the National Cancer Institute.

DNA extraction {#sec2-2}
--------------

Genomic DNA was extracted using QIAamp DNA extraction kit for FFPE tissues (Qiagen, Hilden, Germany) according to the manufacturer's protocol with slight modifications. DNA yield and purity were quantitated and assessed using the Nanodrop.

PCR and Sequencing for mutation screening {#sec2-3}
-----------------------------------------

Polymerase chain reaction (PCR) was performed for all DNA samples using primers designed to amplify *PIK3CA* (exons 9 and 20). Primers sequence were as the following:

*PIK3CA* exon 9 F:(ATTAGCAATGTAAAATTTATTGAAAATGTATTT GCTTTTTC)

*PIK3CA* exon 9 R:(TAAATTCTGCTTTATTTATTCCAATATGGT)

*PIK3CA* exon 20: (CTCAATGATGCTTGGCTCTG)

*PIK3CA* exon 20: (TGGAATCCAGAGTGAGCTTTC)

Amplification reactions were carried out using Taq polymerase (Thermoscientific, MA, USA) in accordance to the manufacturer's protocol. Thermocycling condiotions were an initial denaturation at 95°C for 5 minutes (1 cycle), then 40 cycles of denaturation at 95°C for 1 minute, annealing at 51°C for 90 seconds, elongation at 68°C for 2 minute, followed by final elongation at 68°C for 12 minutes. Nontemplate (DNA) control represented the negative control and was included in every PCR run. The PCR product was then analyzed by gel electrophoresis performed on 2% agarose gel stained with ethidium bromide.

All sequencing reactions were accomplished using the same primers. The PCR products were sequenced using Big Dye terminator mixture. Capillary electrophoresis, sequence analysis, and data collection were done using an automated DNA sequencer. The resulted sequences were compared to human genomic DNA sequence using blast and the mutations numbers were identified using ENSEMBL and Cosmic database.

Statistical analysis {#sec2-4}
--------------------

Chi-square (Fisher's exact) test was used to examine the relation between qualitative variables as appropriate. Survival analysis was made using Kaplan-Meier method. Comparison between two survival curves used log rank test, P-value ≤0.05 was considered significant. All tests were two tailed. Overall survival (OS) was calculated from date of diagnosis till date of death or last follow up.

Results {#sec1-3}
=======

Clinical characteristics of the study cohort {#sec2-5}
--------------------------------------------

In the present study, tumor tissues from 51 breast carcinoma patients with HER-2 positive were analyzed for *PIK3CA* and PTEN mutations. The details of the clinicopathological data of all patients are shown in [Table 1](#T1){ref-type="table"}. The median age of the cohort was 48 years ranging from 28 to 71 years. According to the histopathological data, the majority of the cases were ductal carcinoma (n = 44, 86.3 %), followed by lobular (n = 2, 3.9%) and others (n = 5, 9.8 %). 84.3 % of the tumors were classified as grade II and 15.7 % as grade III. Most of the tumors were found to be node positivite (58.8 %) while about (25%) were negative. According to tumor subtyping with immunohistochemical analysis for ER and PR, 45.1% and 41.2% of the cases showed positive expression respectively.

###### 

Clonicopathological Data of the Study Cohort (n=51)

  Variables           n            \%
  ------------------- ------------ ------
  Age (years)                      
   Median (range)     48 (28-71)   \-
  No. of offspring                 
   Median (range)     3(0-7)       \-
  Marital status                   
   Married            50           98.0
   Widow              1            2.0
  Menopausal status                
   Premenopausal      38           74.5
   Postmenopausal     13           23.5
  Histology                        
   Ductal             44           86.3
   Lobular            2            3.9
   Other              5            9.8
  Tumor grade                      
   II                 43           84.3
   III                8            13.7
  Lymph node status                
   Negative           13           25.5
   Positive                        
   3                  8            15.7
   \> 3               22           43.1
   Missed             8            15.7
  HER2 score                       
   2                  10           19.6
   3                  41           80.4
  ER status                        
   Negative           28           54.9
   Positive           23           45.1
  PR status                        
   Negative           30           58.8
   Positive           21           41.2

PIK3CA mutations type and frequency {#sec2-6}
-----------------------------------

By the mean of direct sequencing, 51 tumor samples from HER2-positive breast cancer were analyzed. In our study cohort, we found that the mutations are hitting both helical and kinase domain of the encoded protein. Eight out of 51 patients (15.7%) harbored *PIK3CA* mutations in either exon 9 or 20, or both. Three out of the eight patients with aberrant *PIK3CA* have mutations in exon 9 and 20. As shown in [table 2](#T2){ref-type="table"}, most of the mutations were missense mutations. Accordingly, the nucleotide substitution is predicted to change the amino acid sequence and consequently the protein function.

###### 

Frequency and Mutation Types of *PIK3CA*

                            cosmic number   Nucleotide change   amino acids   type of mutation   No. of patient   \%       Domain
  ------------ ------------ --------------- ------------------- ------------- ------------------ ---------------- -------- ---------
  PIK3CA       exon9        COSM763         c.1633G\>A          p.E545K       missense           2                3.9      Helical
  COSM297145   c.1634A\>C   p.E545A         missense            1             2.0                Helical                   
  COSM53245    c.1571G\>A   p.R524K         missense            1             2.0                Helical                   
  exon 20      COSM25085    c.3120G\>A      p.M1040I            missense      1                  2.0              Kinase   
  COSM775      c.3140A\>G   p.H1047R        missense            5             9.8                Kinase                    
  COSM87299    c.3147T\>C   p.G1049G        coding silent       1             2.0                Kinase                    

Among the 51 analyzed samples, four patients (7.8%) harbored a missense mutation in exon 9. The detected mutations are changing the codon sequences as the following: (two patients possess E545K, one patients with E545A, and the 4th patient harbored R524K). The three mutations are changing the amino acid sequence of the helical domain of the protein.

Three different mutations in exon 20 were also identified in the present study that change the codon sequence in seven patients (13.7%). These mutations hit the kinase domain. Three amino acids substitution (H1047R, M1040I, and G1049G) were identified.

Mutations correlation to clinicopathological data {#sec2-7}
-------------------------------------------------

[Table 3](#T3){ref-type="table"} displays all correlations between *PIK3CA* mutation status, exon9 and 20 mutation status, and every mutation found and the clinical, pathological and biological parameters of the study cohort. As noted, there is no statistical significant correlation between all *PIK3CA* mutations and any parameter of the clinicopathological data and also for exon 9 or 20. At the histological level, it was observed that *PIK3CA* mutation was frequently found in ductal carcinomas comparable to lobular carcinomas (15.9 vs. 0 %, p = 0.801). The correlation between *PIK3CA* mutations and tumor grade shows that patients with grade II are more frequent than grade III (16.3 vs. 1.3 %, p = 1.00). In addition, there were more cases with *PIK3CA* mutation in lymph node-positive tumors than negative cases (16.7 vs. 15.4 %). The opposite is for the biomarker parameters (ER and PR), The patients with ER/PR negative pattern have *PIK3CA* mutations more than the patients with positive ER/PR (17.9 vs. 13%, p = 1.00) and (14.3 vs. 16.7, p = 1.00) respectively. For HER-2 score we found that there is a slightly significant correlation between the higher score and exon 9 mutations (9.7 vs. 0 %, p = 0.069).

###### 

Correlation between the Different Types of Mutations and ClinicoPathological Data

                      n    PIK3CA Exons 9 and 20   EX9 total   c.1633 G\>A   c.1634 A\>C   c.1571 G\>A   EX20 total   c.3140      c.3140     c.3147                                                                                                                                                                                                 
  ------------------- ---- ----------------------- ----------- ------------- ------------- ------------- ------------ ----------- ---------- -------- ------------- --------- ------- ----------- ---------- ------- ----------- ---------- ------- ----------- ----------- ------- ------------ ---------- ------- ------------ ---------- ------- --
  Age (years)                                                                                                                                                                                                                                                                                                                                       
   ≤50                29   25 (86.8)               4 (13.2)    0.713         27 (93.1)     2 (6.9)       1            28 (96.6)   1 (3.4)    1        29 (100)      0 (0)     0.431   28 (96.6)   1 (3.4)    1       25 (86.8)   4 (13.2)   1       25 (86.8)   4 (13.2)    0.375   29 (100)     0 (0)      0.431   29 (100)     0          0.431   
   \>50               22   18 (81.8)               4 (18.2)                  20 (90.9)     2 (9.1)                    21 (95.5)   1 (4.5)             \`21 (95.5)   1 (4.5)           22 (100)    0 (0)              19 (86.4)   3 (13.6)           21 (95.5)   1 (4.5)             21 (95.5)    1 (4.5)            21 (95.5)    1 (4.5)            
  Menopausal status                                                                                                                                                                                                                                                                                                                                 
   Premenopausal      38   33 (86.8)               5 (13.2)    0.404         36 (94.7)     2 (5.3)       0.695        37 (97.4)   1 (2.6)    0.449    37 (97.4)     1 (2.6)   0.255   37 (97.4)   1 (2.6)    1       34 (89.5)   4 (10.5)   0.352   34 (89.5)   4 (10.5)    1       37 (97.4)    1 (2.6)    1       38 (100)     0          0.255   
   Postmenopausal     13   10 (76.9)               3 (23.1)                  11 (84.6)     2 (15.4)                   12 (92.3)   1 (7.7)             13 (100)      0 (0)             13 (100)    0 (0)              10 (76.9)   3 (23.1)           12 (92.3)   1 (7.7)             13 (100)     0                  12 (92.3)    1 (7.7)            
  Histology                                                                                                                                                                                                                                                                                                                                         
   Ductal             44   37 (84.1)               7 (15.9)    0.801         40 (90.9)     4 (9.1)       0.708        42 (95.5)   2 (4.5)    0.847    43 (97.7)     1 (2.3)   0.922   43 (97.7)   1 (2.3)    0.922   38          6          0.785   40 (90.9)   4 (9.1)     0.66    43 (97.7)    1 (2.3)    0.922   43 (97.7)    1 (2.3)    0.922   
   lobular            2    2 (100)                 0 (0)                     2 (100)       0 (0)                      2 (100)     0 (0)               2 (100)       0 (0)             2 (100)     0 (0)              2 (100)     0 (0)              2 (100)     0 (0)               2 (100)      0 (0)              2 (100)      0 (0)              
   Other              5    4 (80)                  1 (20)                    5 (100)       0 (0)                      5 (100)     0 (0)               5 (100)       0 (0)             5 (100)     0 (0)              4 (80)      1 (20)             4 (80)      1 (20)              5 (100)      0 (0)              5 (100)      0 (0)              
  Tumor grade                                                                                                                                                                                                                                                                                                                                       
   II                 43   36 (83.7)               7 (16.3)    1             40 (93)       3 (7)         0.506        41 (95.3)   2 (4.7)    1        42 (97.7)     1 (2.3)   1.000   43 (100)    0 (0)      0.157   37 (86)     6 (14)     1       39 (90.6)   4 (9.4)     1       42 (97.7)    1 (2.3)    1       42 (97.7)    1 (2.3)    1       
   III                8    7 (87.5)                1 (12.5)                  7 (87.5)      1 (12.5)                   8 (100)     0 (0)               8 (100)       0 (0)             7(87.5)     1 (12.5)           7 (87.5)    1 (12.5)           7 (87.5)    1 (-12.5)           8 (-100)     0                  8 (-100)     0                  
  Lymph node status                                                                                                                                                                                                                                                                                                                                 
   Negative           13   11 (84.6)               2 (15.4)    0.928         11 (84.6)     2 (15.4)      0.284        12 (92.3)   1 (7.7)    0.718    13 (100)      0 (0)     \-      12 (92.3)   1 (7.7)    0.307   11 (84.6)   2 (15.4)   0.928   11 (84.6)   2 (15.4)    0.851   13 (100)     0 (0)      0.613   13 (100)     0 (0)      0.613   
   Positive 1(3       8    7 (87.5)                1 (12.5                   8 (100)       0 (0)                      8 (100)     0 (0)               8 (100)       0 (0)             8 (100)     0 (0)              7 (87.5)    1 (12.5)           7 (87.5)    1 (12.5)            8 (100)      0 (0)              8 (100)      0 (0)              
   Positive \> 3      22   18 (81.8)               4 (18.8)                  21 (95.5)     1 (4.5)                    21 (95.5)   1 (4.5)             22 (100)      0 (0)             22 (100)    0 (0)              18 (81.8)   4 (18.8)           20 (90.9)   2 (9.1)             21 (95.5)    1 (4.5)            21 (95.5)    1 (4.5)            
  HER2 score                                                                                                                                                                                                                                                                                                                                        
   2                  10   10 (100)                0 (0)       0.329         10 (100)      0 (0)         0.069        10 (100)    0 (0)      1        10 (100)      0 (0)     1       10 (100)    0 (0)      1       10 (100)    0 (0)      0.32    10 (100)    0           0.569   10 (100)     0 (0)      1       10 (100)     0 (0)      1       
   3                  41   33 (80.5)               8 (19.5)                  37 (90.2)     4 (9.8)                    39 (95.1)   2 (4.9)             40 (97.6)     1 (2.4)           40 (97.6)   1 (2.4)            34 (82.9)   7 (17.1)           36 (87.8)   5 (12.2)            40 (-97.6)   1 (-2.4)           40 (-97.6)   1 (-2.4)           
  ER                                                                                                                                                                                                                                                                                                                                                
   positive           23   20 (97)                 3 (3)       0.715         22 (95.7)     1 (4.3)       1            23 (100)    0          0.495    22 (95.7)     1 (4.3)   1       22 (95.7)   1 (4.3)    0.451   20 (97)     3 (3)      1       20 (97)     3 (3)       0.647   23 (100)     0          1       23 (100)     0          1       
   negative           28   23 (82.1)               5 (17.9)                  25 (89.3)     3 (10.7)                   26 (82.9)   2 (17.1)            28 (100)      0 (0)             28 (100)    0 (0)              24 (85.7)   4 (14.3)           26 (82.9)   2 (17.1)            27 (94.4)    1 (5.6)            27 (94.4)    1 (5.6)            
  PR                                                                                                                                                                                                                                                                                                                                                
   positive           21   18 (85.7)               3 (14.3)    1             20 (95.2)     1 (4.8)       1            21 (100)    0 (0)      0.506    21 (100)      0 (0)     1       20 (95.2)   1 (4.8)    0.412   18 (85.7)   3 (14.3)   1       18 (85.7)   3 (14.3)    0.637   21 (100)     0          1       21 (100)     0          1       
   negative           30   25 (83.3)               5 (16.7)                  27 (90)       3 (10)                     28 (93.3)   2 (6.7)             29 (96.7)     1 (3.3)           30 (100)    0 (0)              26 (86.7)   4 (13.3)           28 (93.3)   2 (6.7)             29 (96.7)    1 (3.3)            29 (96.7)    1 (3.3)            

Survival analysis {#sec2-8}
-----------------

The median follow-up time was 35.2 months (ranging from 1.0 to 110.1months); OS of BC patients is shown in [Fig (2)](#F1 F2){ref-type="fig"}. There is no statistically significant association between BC patients' OS and clinicopathological data of studied cohort or between OS and PIK3 mutation as shown in [Table (4)](#T4){ref-type="table"}.

###### 

Correlation of Overall Survival (OS) with PIK3CA Mutation Status and with Clinicopathological Data

  Variable                                                         n    Cumulative survival at 36 months   P-value
  ---------------------------------------------------------------- ---- ---------------------------------- ----------------------------------
  All                                                              48   86.9%                              \_
  PIK3CA                                                                                                   
   Wild                                                            40   87.4%                              0.818
   Mutant                                                          8    85.7%                              
  PIK3CA exon 9                                                                                            
   Wild                                                            46   85.4%                              [\*](#t4f1){ref-type="table-fn"}
   Mutant                                                          2    100.0%                             
  c.1633 G\>A                                                                                              
   Wild                                                            46   100.0%                             [\*](#t4f1){ref-type="table-fn"}
   Mutant                                                          2    86.1%                              
  c.1634 A\>C                                                                                              
   Wild                                                            47   86.6%                              [\*](#t4f1){ref-type="table-fn"}
   Mutant                                                          1    100.0%                             
  c.1571 G\>A                                                                                              
   Wild                                                            47   86.5%                              [\*](#t4f1){ref-type="table-fn"}
   Mutant                                                          1    100.0%                             
  PIK3CA exon 20                                                                                           
   Wild                                                            41   87.6%                              0.712
   Mutant                                                          7    83.3%                              
  c.3147 T\>C                                                                                              
   Wild                                                            47   86.6%                              [\*](#t4f1){ref-type="table-fn"}
   Mutant                                                          1    100.0%                             
  c.3140 A\>G                                                                                              
   Wild                                                            43   88.2%                              0.423
   Mutant                                                          5    75.0%                              
  c.3120 G\>A                                                                                              
   Wild                                                            47   86.5%                              [\*](#t4f1){ref-type="table-fn"}
   Mutant                                                          1    100.0%                             
  Relation of overall survival (OS) and clinicopathological data                                           
  Age                                                                                                      
   ≤50                                                             28   84.9%                              0.404
   \>50                                                            20   88.9%                              
  Menopausal status                                                                                        
   Premenopausal                                                   36   87.4%                              0.827
   Postmenopausal                                                  12   80.0%                              
  Histology                                                                                                
   IDC                                                             42   89.9%                              0.083
   Others                                                          6    66.7%                              
  Tumor grade                                                                                              
   II                                                              40   83.3%                              0.242
   III                                                             8    100.0%                             
  Lymph node                                                                                               
   Negative                                                        12   91.7%                              0.823
   Positive 1-3                                                    8    85.7%                              
   Positive \>3                                                    22   79.0%                              
  HER2 score                                                                                               
  2                                                                9    100.0%                             0.277
  3                                                                39   83.9%                              
  ER                                                                                                       
   Positive                                                        20   89.2%                              0.828
   Negative                                                        28   83.7%                              
  PR                                                                                                       
   Positive                                                        20   94.7%                              0.274
   Negative                                                        28   79.5                               

, no P-value because of small no of cases within subgroups; No median survival because more than half of patients were still alive till end of the study

![Partial Chromatograms of *PIK3CA* Mutations: a, c and e, *PIK3CA* Exon 9 Mutations (E545A, E545K and R524K); b, d, and f, Wild-Type sequences. g, *PIK3CA* exon 20 Mutation (H1047R); h, Wild-Type Sequence. Arrows, Position of the Missense Mutationas](APJCP-18-57-g001){#F1}
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Discussion {#sec1-4}
==========

According to GLOBOCAN 2012, breast cancer is the second most common malignancy worldwide and the most frequent cancer in women. A slight majority of cases were in less developed countries rather than developed world. Worldwide, breast cancer is the fifth cause of malignancy death overall. In the less developed region, it is the most frequent cause of cancer death in women (Ferlay et al., 2015). Breast carcinomas are heterogeneous group of tumors which differ morphologically and at the molecular level (Samuels et al., 2005; Engelman, 2009). HER2-positive BC is the most aggressive subtype of BC, where the patient has a decreased overall survival and may have differential responses to a variety of chemotherapeutic and hormonal agents (Berry et al., 2000). In the HER2-positive patients, using therapeutic reagents that target the human epidermal growth factor receptor-2 (HER2) has improved the outcomes in combination with chemotherapy (Romond et al., 2005; Swain et al., 2015). PI3K pathway is the downstream signaling for HER2 and is frequently activated in cancer (Vivanco and Sawyers, 2002). Recently, Loibl et al., (2016) carried out a meta-analysis in which they studied whether *PIK3CA* activating mutations are linked to lower sensitivity to neoadjuvant therapy. They found that overall *PIK3CA* mutations in HER2-positive significantly decreased the pathological complete response (pCR) compared to the wild type. These findings point out that *PIK3CA* mutations status could potentially act as a predictive marker for HER2-positive cancer.

In the present study, we carried out a sequence analysis for most common mutated exons of *PIK3CA* (exons 9 and 20) in 51 patients. So, this study was executed to calculate the mutation frequency and correlation to clinicopathological data in Egyptian HER2-positive breast cancer patients. To our knowledge, our study is the first study to evaluate *PIK3CA* mutations in HER2-positive patients in Egypt. The only available study (on Pubmed) in Egypt was done in HER2-negative breast cancer patients and *PIK3CA* mutation status was tested in 24 patients. In this previous study, they found 7 out of 24 HER2-negative breast cancer patients (29.2%) in Egypt (Azim et al., 2016). In the present study, we found less frequent overall *PIK3CA* mutations (eight out of 51 patients) were detected in HER2-positive breast cancer (15.7%). However, it is difficult to conclude that the frequency of *PIK3CA* mutations is higher in HER2-negative in the Egyptian patients due to the small number of patients in both cohorts. Nevertheless, Arsenic et al. (Arsenic et al., 2014) found that the *PIK3CA* mutations rate was higher in HR(+)/HER2(-), whereas the lowest mutation rate was observed in HR(+)/HER2(+) in their study. In contrary, another study found that the *PIK3CA* somatic mutations in hormonal positive/HER2-positive are more common, though the data are not significant (Ahmad et al., 2016). The peer studies showed that *PIK3CA* mutations frequency is very variable across the world (Li et al., 2006; Kalinsky et al., 2009; Loibl et al., 2014; Ross et al., 2015; Ahmad et al., 2016; Sudhakar et al., 2016). The percentage of the detected mutations in our cohort is comparable to HER2-positive subtype in a recent Indian study (Ahmad et al., 2016).

As reviewed previously (Dirican et al., 2016), around 80% of *PIK3CA* mutations occur in exons 9 and 20. These two exons have mostly the "hot spot" of *PIK3CA* gene. Exons 9 and 20 encode the helical and kinase domains of the protein. the mutations of this region activate the gene with constant auto-phosphorylation. In the present data, mutations in exon 20 which encodes the kinase domain are more frequent than those in exon 9 (encodes the helical domain). These data are in alignment with several previous studies (Li et al., 2006; Loibl et al., 2014; Arsenic et al., 2015; Ahmad et al., 2016). From the detected mutations, three missense mutations were considered as hot spots which are at amino acid number 524, 545, and 1047 as described previously in the results section.

Considering the clinicopathological data, the *PIK3CA* mutations didn't show any significant association with clinical and pathological data which was shown in many previous studies (Harle et al., 2013; Loibl et al., 2014; Ahmad et al., 2016). However, our results show tendency of having *PIK3CA* mutation in higher HER2 score (data are not significant) with higher mutations rate in exon 9 (with trend to be significant; p = 0.069). Consistently with previous studies (Dunlap et al., 2010; Kandula et al., 2013; Arsenic et al., 2015; Ahmad et al., 2016), *PIK3CA* mutations were more frequent in grade II tumors than patients with grade III which could be referred to involvement of the mutations at the onset of the carcinogenesis process. The survival data are not significant in our study which could be related to the limited number of patients in the investigated cohort.

In summary, the present study is the first one which investigating *PIK3CA* mutations in HER2-positive breast cancer patients in Egypt. The frequency reported in this study was comparable to the international frequencies. Interestingly, the frequency found in HER2-positive patients was less than HER2-negative patient reported in another study (Azim et al., 2016). However, the number of patients contributed in this study is not enough for solid conclusion. Even though, we are highlighting the frequency which could be useful in the nearby future research and clinical application of *PIK3CA* as a predictive marker for anti-HER2 therapy.
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